首页> 外文期刊>Journal of Bioscience and Bioengineering >Classification of Intramural Metastases and Lymph Node Metastases of Esophageal Cancer from Gene Expression Based on Boosting and Projective Adaptive Resonance Theory
【24h】

Classification of Intramural Metastases and Lymph Node Metastases of Esophageal Cancer from Gene Expression Based on Boosting and Projective Adaptive Resonance Theory

机译:基于Boosting和投射自适应共振理论的食管癌壁内转移和淋巴结转移的基因表达分类

获取原文
获取原文并翻译 | 示例
       

摘要

Esophageal cancer is a well-known cancer with poorer prognosis than other cancers.An optimal and individualized treatment protocol based on accurate diagnosis is urgently needed to improve the treatment of cancer patients.For this purpose,it is important to develop a sophisticated algorithm that can manage a large amount of data,such as gene expression data from DNA microarrays,for optimal and individualized diagnosis.Marker gene selection is essential in the analysis of gene expression data.We have already developed a combination method of the use of the projective adaptive resonance theory and that of a boosted fuzzy classifier with the SWEEP operator denoted PART-BFCS.This method is superior to other methods,and has four features,namely fast calculation,accurate prediction,reliable prediction,and rule extraction.In this study,we applied this method to analyze microarray data obtained from esophageal cancer patients.A combination method of PART-BFCS and the U-test was also investigated.It was necessary to use a specific type of BFCS,namely,BFCS-1,2,because the esophageal cancer data were very complexity.PART-BFCS and PART-BFCS with the U-test models showed higher performances than two conventional methods,namely,kappa-nearest neighbor(kNN)and weighted voting(WV).The genes including CDK6 could be found by our methods and excellent IF-THEN rules could be extracted.The genes selected in this study have a high potential as new diagnosis markers for esophageal cancer.These results indicate that the new methods can be used in marker gene selection for the diagnosis of cancer patients.
机译:食管癌是比其他癌症预后差的著名癌症。迫切需要基于准确诊断的最佳个性化治疗方案以改善癌症患者的治疗。为此,开发一种复杂的算法非常重要。管理大量数据(例如来自DNA芯片的基因表达数据)以进行最佳和个性化诊断。标记基因选择对于分析基因表达数据至关重要。我们已经开发了一种结合使用投射自适应共振的方法该理论优于带有SWEEP运算符的增强型模糊分类器的理论,即PART-BFCS。该方法优于其他方法,具有快速计算,准确预测,可靠预测和规则提取四个特征。同时分析了食管癌患者的微阵列数据。同时研究了PART-BFCS和U检验的组合方法ed。由于食管癌数据非常复杂,因此有必要使用特定类型的BFCS,即BFCS-1,2,采用U检验模型的PART-BFCS和PART-BFCS显示出比两种常规方法更高的性能。我们的方法可以找到包括CDK6在内的基因,并提取出优良的IF-THEN规则。本研究中选择的基因具有很高的潜在诊断价值。这些结果表明,新方法可用于选择标记基因以诊断癌症患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号